Podcast appearances and mentions of Ian W Flinn

Featuring perspectives from Dr Joshua Brody, Dr Ian W Flinn and Dr Tycel Phillips, including the following topics: Introduction: CD3 Bispecific Antibodies in the Community Oncology Setting (0:00) Integration of Bispecific Antibody Therapy into the Management of Diffuse Large B-Cell Lymphoma — Dr Phillips (18:13) Current and Future Role of Bispecific Antibodies in Follicular Lymphoma and Other B-Cell Lymphomas — Dr Flinn (41:20) Tolerability and Other Practical Considerations with the Use of Bispecific Antibody Therapy — Dr Brody(50:49) CME information and select publications

Dr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASCO2024/BispecificLymphoma).

Dr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas.

Featuring perspectives from Dr Ian W Flinn, including the following topics: Hodgkin Lymphoma Introduction (0:00) Case: A man in his late 30s with well-controlled HIV and newly diagnosed Stage IV classic Hodgkin lymphoma receives brentuximab vedotin with doxorubicin/vinblastine/dacarbazine (AVD) — Neil Morganstein, MD (2:30) Case: A man in his early 60s with classic Hodgkin lymphoma with a left lower lung mass and extensive regional lymphadenopathy receives brentuximab vedotin with AVD on the Phase III SWOG-S1826 trial — Ranju Gupta, MD (6:45) Mantle Cell Lymphoma (MCL) Case: A man in his late 50s with newly diagnosed MCL blastoid variant — Zanetta S Lamar, MD (16:27) Case: A man in his mid 50s with newly diagnosed Stage IV MCL — Shams Bufalino, MD (21:23) Follicular Lymphoma Case: A man in his mid 60s with incidental diagnosis of Grade IIIA follicular lymphoma after admission to the hospital for a stroke — Bhavana (Tina) Bhatnagar, DO (36:28) Case: A woman in her late 30s with extensive lymphadenopathy is diagnosed with Grade I/II follicular lymphoma and receives bendamustine/rituximab — Dr Morganstein (39:04) Diffuse Large B-Cell Lymphoma (DLBCL) Case: A physically independent man in his early 80s with DLBCL and multiple comorbidities, including cardiac issues and peripheral neuropathy, experiences disease progression after R-GCVP — Syed F Zafar MD (49:53) Case: A man in his mid 70s who presented with rapidly progressive proptosis of the left eye is diagnosed with DLBCL and receives R-CHOP and methotrexate CNS prophylaxis — Dr Lamar (55:21) CME information and select publications

Featuring a discussion on the management of non-Hodgkin lymphoma with Dr Ian W Flinn, moderated by Dr Neil Love.

Dr Ian W Flinn discusses the management of Hodgkin and non-Hodgkin lymphoma. CME information and select publications here (http://www.researchtopractice.com/MTPLymphoma23/)

Featuring perspectives from Drs Ajai Chari, Ian Flinn, Nikhil Munshi and Laurie Sehn, including the following topics: Part 1: Case Presentations and Clinical Decision-Making (0:00) Case: A man in his early 70s with diffuse large B-cell lymphoma (DLBCL) arising from follicular lymphoma — Ian W Flinn, MD, PhD (3:46) Case: A man in his late 50s with nongerminal center B-cell-like subtype DLBCL — Laurie H Sehn, MD, MPH (15:57) Case: CAR-T therapy during the pandemic — Nikhil C Munshi, MD (22:16) Case: Anti-BCMC bispecific in triple-class and penta-drug refractory disease — Ajai Chari, MD (33:54) CAR-T therapy for non-Hodgkin lymphoma — Dr Flinn (37:09) Bispecifics for non-Hodgkin lymphoma — Dr Sehn (51:48) CAR-T therapy for multiple myeloma — Dr Munshi (1:13:23) Bispecifics for multiple myeloma — Dr Chari (1:26:14) CME information and select publications

Go online to PeerView.com/NZY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Modern management of chronic lymphocytic leukemia (CLL) has been transformed by innovative therapeutics, including BTK and BCL-2 inhibitors, in a range of patient populations and treatment settings—but what is the next step? In this activity, an expert clinician addresses that question and reviews evidence on emerging targeted options and novel combination strategies likely to affect patient care. Upon completion of this accredited CE activity, participants should be better able to: Discuss genetic/molecular, clinical, or patient-related factors that can guide therapeutic selection in patients with treatment-naïve or relapsed/refractory CLL, Summarize current safety and efficacy evidence related to the use of novel and emerging therapeutics, including BTK, PI3K, and BCL-2 inhibitors and novel antibodies, across the spectrum of CLL, Select personalized initial or sequential treatment regimens with novel and emerging components for patients with treatment-naïve or relapsed/refractory CLL, including in the context of a clinical trial.

Go online to PeerView.com/NZY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Modern management of chronic lymphocytic leukemia (CLL) has been transformed by innovative therapeutics, including BTK and BCL-2 inhibitors, in a range of patient populations and treatment settings—but what is the next step? In this activity, an expert clinician addresses that question and reviews evidence on emerging targeted options and novel combination strategies likely to affect patient care. Upon completion of this accredited CE activity, participants should be better able to: Discuss genetic/molecular, clinical, or patient-related factors that can guide therapeutic selection in patients with treatment-naïve or relapsed/refractory CLL, Summarize current safety and efficacy evidence related to the use of novel and emerging therapeutics, including BTK, PI3K, and BCL-2 inhibitors and novel antibodies, across the spectrum of CLL, Select personalized initial or sequential treatment regimens with novel and emerging components for patients with treatment-naïve or relapsed/refractory CLL, including in the context of a clinical trial.

Go online to PeerView.com/NZY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Modern management of chronic lymphocytic leukemia (CLL) has been transformed by innovative therapeutics, including BTK and BCL-2 inhibitors, in a range of patient populations and treatment settings—but what is the next step? In this activity, an expert clinician addresses that question and reviews evidence on emerging targeted options and novel combination strategies likely to affect patient care. Upon completion of this accredited CE activity, participants should be better able to: Discuss genetic/molecular, clinical, or patient-related factors that can guide therapeutic selection in patients with treatment-naïve or relapsed/refractory CLL, Summarize current safety and efficacy evidence related to the use of novel and emerging therapeutics, including BTK, PI3K, and BCL-2 inhibitors and novel antibodies, across the spectrum of CLL, Select personalized initial or sequential treatment regimens with novel and emerging components for patients with treatment-naïve or relapsed/refractory CLL, including in the context of a clinical trial.

Go online to PeerView.com/NZY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Modern management of chronic lymphocytic leukemia (CLL) has been transformed by innovative therapeutics, including BTK and BCL-2 inhibitors, in a range of patient populations and treatment settings—but what is the next step? In this activity, an expert clinician addresses that question and reviews evidence on emerging targeted options and novel combination strategies likely to affect patient care. Upon completion of this accredited CE activity, participants should be better able to: Discuss genetic/molecular, clinical, or patient-related factors that can guide therapeutic selection in patients with treatment-naïve or relapsed/refractory CLL, Summarize current safety and efficacy evidence related to the use of novel and emerging therapeutics, including BTK, PI3K, and BCL-2 inhibitors and novel antibodies, across the spectrum of CLL, Select personalized initial or sequential treatment regimens with novel and emerging components for patients with treatment-naïve or relapsed/refractory CLL, including in the context of a clinical trial.

Go online to PeerView.com/NZY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Modern management of chronic lymphocytic leukemia (CLL) has been transformed by innovative therapeutics, including BTK and BCL-2 inhibitors, in a range of patient populations and treatment settings—but what is the next step? In this activity, an expert clinician addresses that question and reviews evidence on emerging targeted options and novel combination strategies likely to affect patient care. Upon completion of this accredited CE activity, participants should be better able to: Discuss genetic/molecular, clinical, or patient-related factors that can guide therapeutic selection in patients with treatment-naïve or relapsed/refractory CLL, Summarize current safety and efficacy evidence related to the use of novel and emerging therapeutics, including BTK, PI3K, and BCL-2 inhibitors and novel antibodies, across the spectrum of CLL, Select personalized initial or sequential treatment regimens with novel and emerging components for patients with treatment-naïve or relapsed/refractory CLL, including in the context of a clinical trial.

Go online to PeerView.com/NZY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Modern management of chronic lymphocytic leukemia (CLL) has been transformed by innovative therapeutics, including BTK and BCL-2 inhibitors, in a range of patient populations and treatment settings—but what is the next step? In this activity, an expert clinician addresses that question and reviews evidence on emerging targeted options and novel combination strategies likely to affect patient care. Upon completion of this accredited CE activity, participants should be better able to: Discuss genetic/molecular, clinical, or patient-related factors that can guide therapeutic selection in patients with treatment-naïve or relapsed/refractory CLL, Summarize current safety and efficacy evidence related to the use of novel and emerging therapeutics, including BTK, PI3K, and BCL-2 inhibitors and novel antibodies, across the spectrum of CLL, Select personalized initial or sequential treatment regimens with novel and emerging components for patients with treatment-naïve or relapsed/refractory CLL, including in the context of a clinical trial.

Go online to PeerView.com/MBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent emergence and regulatory approval of multiple novel agent classes, such as Bruton's tyrosine kinase (BTK) inhibitors and immunomodulatory drugs (IMiDs), in the management of mantle cell lymphoma (MCL) has offered clinicians and patients a greater variety of effective therapeutic options in this challenging clinical setting. At the same time, researchers continue to assess the potential of BCL-2 targeting agents and BTK inhibitor combinations, while new science has led to the regulatory approval of chimeric antigen receptor (CAR)-T cell therapy in relapsed disease. In this “Clinical Consults” activity, experts will offer guidance on key findings that have decisively turned the field away from chemotherapy-centric care. Upon completion of this activity, participants should be better able to: Summarize current recommendations for managing newly diagnosed and relapsed/refractory MCL based on factors such as treatment history, disease characteristics, or need for aggressive therapy, Discuss evidence surrounding novel treatment regimens that include BTK inhibitor, BCL-2 inhibitor, immunomodulatory, or adoptive cell therapy components across the MCL disease spectrum, Recommend therapy with novel components for the management of patients with MCL after consideration of baseline prognostic factors and/or treatment history, Manage the unique spectrum of adverse events associated with novel therapeutics in patients with MCL.

Go online to PeerView.com/MBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent emergence and regulatory approval of multiple novel agent classes, such as Bruton's tyrosine kinase (BTK) inhibitors and immunomodulatory drugs (IMiDs), in the management of mantle cell lymphoma (MCL) has offered clinicians and patients a greater variety of effective therapeutic options in this challenging clinical setting. At the same time, researchers continue to assess the potential of BCL-2 targeting agents and BTK inhibitor combinations, while new science has led to the regulatory approval of chimeric antigen receptor (CAR)-T cell therapy in relapsed disease. In this “Clinical Consults” activity, experts will offer guidance on key findings that have decisively turned the field away from chemotherapy-centric care. Upon completion of this activity, participants should be better able to: Summarize current recommendations for managing newly diagnosed and relapsed/refractory MCL based on factors such as treatment history, disease characteristics, or need for aggressive therapy, Discuss evidence surrounding novel treatment regimens that include BTK inhibitor, BCL-2 inhibitor, immunomodulatory, or adoptive cell therapy components across the MCL disease spectrum, Recommend therapy with novel components for the management of patients with MCL after consideration of baseline prognostic factors and/or treatment history, Manage the unique spectrum of adverse events associated with novel therapeutics in patients with MCL.

Go online to PeerView.com/MBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent emergence and regulatory approval of multiple novel agent classes, such as Bruton's tyrosine kinase (BTK) inhibitors and immunomodulatory drugs (IMiDs), in the management of mantle cell lymphoma (MCL) has offered clinicians and patients a greater variety of effective therapeutic options in this challenging clinical setting. At the same time, researchers continue to assess the potential of BCL-2 targeting agents and BTK inhibitor combinations, while new science has led to the regulatory approval of chimeric antigen receptor (CAR)-T cell therapy in relapsed disease. In this “Clinical Consults” activity, experts will offer guidance on key findings that have decisively turned the field away from chemotherapy-centric care. Upon completion of this activity, participants should be better able to: Summarize current recommendations for managing newly diagnosed and relapsed/refractory MCL based on factors such as treatment history, disease characteristics, or need for aggressive therapy, Discuss evidence surrounding novel treatment regimens that include BTK inhibitor, BCL-2 inhibitor, immunomodulatory, or adoptive cell therapy components across the MCL disease spectrum, Recommend therapy with novel components for the management of patients with MCL after consideration of baseline prognostic factors and/or treatment history, Manage the unique spectrum of adverse events associated with novel therapeutics in patients with MCL.

Go online to PeerView.com/MBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent emergence and regulatory approval of multiple novel agent classes, such as Bruton's tyrosine kinase (BTK) inhibitors and immunomodulatory drugs (IMiDs), in the management of mantle cell lymphoma (MCL) has offered clinicians and patients a greater variety of effective therapeutic options in this challenging clinical setting. At the same time, researchers continue to assess the potential of BCL-2 targeting agents and BTK inhibitor combinations, while new science has led to the regulatory approval of chimeric antigen receptor (CAR)-T cell therapy in relapsed disease. In this “Clinical Consults” activity, experts will offer guidance on key findings that have decisively turned the field away from chemotherapy-centric care. Upon completion of this activity, participants should be better able to: Summarize current recommendations for managing newly diagnosed and relapsed/refractory MCL based on factors such as treatment history, disease characteristics, or need for aggressive therapy, Discuss evidence surrounding novel treatment regimens that include BTK inhibitor, BCL-2 inhibitor, immunomodulatory, or adoptive cell therapy components across the MCL disease spectrum, Recommend therapy with novel components for the management of patients with MCL after consideration of baseline prognostic factors and/or treatment history, Manage the unique spectrum of adverse events associated with novel therapeutics in patients with MCL.

Go online to PeerView.com/MBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent emergence and regulatory approval of multiple novel agent classes, such as Bruton's tyrosine kinase (BTK) inhibitors and immunomodulatory drugs (IMiDs), in the management of mantle cell lymphoma (MCL) has offered clinicians and patients a greater variety of effective therapeutic options in this challenging clinical setting. At the same time, researchers continue to assess the potential of BCL-2 targeting agents and BTK inhibitor combinations, while new science has led to the regulatory approval of chimeric antigen receptor (CAR)-T cell therapy in relapsed disease. In this “Clinical Consults” activity, experts will offer guidance on key findings that have decisively turned the field away from chemotherapy-centric care. Upon completion of this activity, participants should be better able to: Summarize current recommendations for managing newly diagnosed and relapsed/refractory MCL based on factors such as treatment history, disease characteristics, or need for aggressive therapy, Discuss evidence surrounding novel treatment regimens that include BTK inhibitor, BCL-2 inhibitor, immunomodulatory, or adoptive cell therapy components across the MCL disease spectrum, Recommend therapy with novel components for the management of patients with MCL after consideration of baseline prognostic factors and/or treatment history, Manage the unique spectrum of adverse events associated with novel therapeutics in patients with MCL.

Go online to PeerView.com/MBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent emergence and regulatory approval of multiple novel agent classes, such as Bruton's tyrosine kinase (BTK) inhibitors and immunomodulatory drugs (IMiDs), in the management of mantle cell lymphoma (MCL) has offered clinicians and patients a greater variety of effective therapeutic options in this challenging clinical setting. At the same time, researchers continue to assess the potential of BCL-2 targeting agents and BTK inhibitor combinations, while new science has led to the regulatory approval of chimeric antigen receptor (CAR)-T cell therapy in relapsed disease. In this “Clinical Consults” activity, experts will offer guidance on key findings that have decisively turned the field away from chemotherapy-centric care. Upon completion of this activity, participants should be better able to: Summarize current recommendations for managing newly diagnosed and relapsed/refractory MCL based on factors such as treatment history, disease characteristics, or need for aggressive therapy, Discuss evidence surrounding novel treatment regimens that include BTK inhibitor, BCL-2 inhibitor, immunomodulatory, or adoptive cell therapy components across the MCL disease spectrum, Recommend therapy with novel components for the management of patients with MCL after consideration of baseline prognostic factors and/or treatment history, Manage the unique spectrum of adverse events associated with novel therapeutics in patients with MCL.

Go online to PeerView.com/MBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent emergence and regulatory approval of multiple novel agent classes, such as Bruton's tyrosine kinase (BTK) inhibitors and immunomodulatory drugs (IMiDs), in the management of mantle cell lymphoma (MCL) has offered clinicians and patients a greater variety of effective therapeutic options in this challenging clinical setting. At the same time, researchers continue to assess the potential of BCL-2 targeting agents and BTK inhibitor combinations, while new science has led to the regulatory approval of chimeric antigen receptor (CAR)-T cell therapy in relapsed disease. In this “Clinical Consults” activity, experts will offer guidance on key findings that have decisively turned the field away from chemotherapy-centric care. Upon completion of this activity, participants should be better able to: Summarize current recommendations for managing newly diagnosed and relapsed/refractory MCL based on factors such as treatment history, disease characteristics, or need for aggressive therapy, Discuss evidence surrounding novel treatment regimens that include BTK inhibitor, BCL-2 inhibitor, immunomodulatory, or adoptive cell therapy components across the MCL disease spectrum, Recommend therapy with novel components for the management of patients with MCL after consideration of baseline prognostic factors and/or treatment history, Manage the unique spectrum of adverse events associated with novel therapeutics in patients with MCL.

Go online to PeerView.com/MBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent emergence and regulatory approval of multiple novel agent classes, such as Bruton's tyrosine kinase (BTK) inhibitors and immunomodulatory drugs (IMiDs), in the management of mantle cell lymphoma (MCL) has offered clinicians and patients a greater variety of effective therapeutic options in this challenging clinical setting. At the same time, researchers continue to assess the potential of BCL-2 targeting agents and BTK inhibitor combinations, while new science has led to the regulatory approval of chimeric antigen receptor (CAR)-T cell therapy in relapsed disease. In this “Clinical Consults” activity, experts will offer guidance on key findings that have decisively turned the field away from chemotherapy-centric care. Upon completion of this activity, participants should be better able to: Summarize current recommendations for managing newly diagnosed and relapsed/refractory MCL based on factors such as treatment history, disease characteristics, or need for aggressive therapy, Discuss evidence surrounding novel treatment regimens that include BTK inhibitor, BCL-2 inhibitor, immunomodulatory, or adoptive cell therapy components across the MCL disease spectrum, Recommend therapy with novel components for the management of patients with MCL after consideration of baseline prognostic factors and/or treatment history, Manage the unique spectrum of adverse events associated with novel therapeutics in patients with MCL.

Go online to PeerView.com/MBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent emergence and regulatory approval of multiple novel agent classes, such as Bruton's tyrosine kinase (BTK) inhibitors and immunomodulatory drugs (IMiDs), in the management of mantle cell lymphoma (MCL) has offered clinicians and patients a greater variety of effective therapeutic options in this challenging clinical setting. At the same time, researchers continue to assess the potential of BCL-2 targeting agents and BTK inhibitor combinations, while new science has led to the regulatory approval of chimeric antigen receptor (CAR)-T cell therapy in relapsed disease. In this “Clinical Consults” activity, experts will offer guidance on key findings that have decisively turned the field away from chemotherapy-centric care. Upon completion of this activity, participants should be better able to: Summarize current recommendations for managing newly diagnosed and relapsed/refractory MCL based on factors such as treatment history, disease characteristics, or need for aggressive therapy, Discuss evidence surrounding novel treatment regimens that include BTK inhibitor, BCL-2 inhibitor, immunomodulatory, or adoptive cell therapy components across the MCL disease spectrum, Recommend therapy with novel components for the management of patients with MCL after consideration of baseline prognostic factors and/or treatment history, Manage the unique spectrum of adverse events associated with novel therapeutics in patients with MCL.

Go online to PeerView.com/MBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent emergence and regulatory approval of multiple novel agent classes, such as Bruton's tyrosine kinase (BTK) inhibitors and immunomodulatory drugs (IMiDs), in the management of mantle cell lymphoma (MCL) has offered clinicians and patients a greater variety of effective therapeutic options in this challenging clinical setting. At the same time, researchers continue to assess the potential of BCL-2 targeting agents and BTK inhibitor combinations, while new science has led to the regulatory approval of chimeric antigen receptor (CAR)-T cell therapy in relapsed disease. In this “Clinical Consults” activity, experts will offer guidance on key findings that have decisively turned the field away from chemotherapy-centric care. Upon completion of this activity, participants should be better able to: Summarize current recommendations for managing newly diagnosed and relapsed/refractory MCL based on factors such as treatment history, disease characteristics, or need for aggressive therapy, Discuss evidence surrounding novel treatment regimens that include BTK inhibitor, BCL-2 inhibitor, immunomodulatory, or adoptive cell therapy components across the MCL disease spectrum, Recommend therapy with novel components for the management of patients with MCL after consideration of baseline prognostic factors and/or treatment history, Manage the unique spectrum of adverse events associated with novel therapeutics in patients with MCL.

Go online to PeerView.com/RZK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PeerView's latest MasterClass and “Tumor Board” on demand activity is based on a live symposium at the 2019 hematologic malignancies meeting in Chicago and covers the ongoing integration of novel and next-generation therapeutics in the management of several B-cell malignancies, including follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL). This educational video activity combines scientific discussions with more practically focused case and tumor board-style elements in order to illustrate how innovative therapies, such as BTK, PI3K, and BCL-2 inhibitors, as well as IMiD-based regimens, are increasingly surpassing conventional options in the management of lymphoid cancers. Upon completion of this activity, participants should be better able to: Summarize recent efficacy and safety data associated with novel therapies, including BCR inhibitors, next-generation antibodies, BCL-2 inhibitors, and IMiDs, used to treat B-cell malignancies, Recommend novel agent classes for the treatment of newly diagnosed or relapsed/refractory B-cell malignancies, including for patients with CLL, FL, or MCL, Manage the unique spectrum of adverse events associated with the use of novel therapies in the management of B-cell malignancies

Go online to PeerView.com/RZK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PeerView's latest MasterClass and “Tumor Board” on demand activity is based on a live symposium at the 2019 hematologic malignancies meeting in Chicago and covers the ongoing integration of novel and next-generation therapeutics in the management of several B-cell malignancies, including follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL). This educational video activity combines scientific discussions with more practically focused case and tumor board-style elements in order to illustrate how innovative therapies, such as BTK, PI3K, and BCL-2 inhibitors, as well as IMiD-based regimens, are increasingly surpassing conventional options in the management of lymphoid cancers. Upon completion of this activity, participants should be better able to: Summarize recent efficacy and safety data associated with novel therapies, including BCR inhibitors, next-generation antibodies, BCL-2 inhibitors, and IMiDs, used to treat B-cell malignancies, Recommend novel agent classes for the treatment of newly diagnosed or relapsed/refractory B-cell malignancies, including for patients with CLL, FL, or MCL, Manage the unique spectrum of adverse events associated with the use of novel therapies in the management of B-cell malignancies

Go online to PeerView.com/RZK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PeerView's latest MasterClass and “Tumor Board” on demand activity is based on a live symposium at the 2019 hematologic malignancies meeting in Chicago and covers the ongoing integration of novel and next-generation therapeutics in the management of several B-cell malignancies, including follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL). This educational video activity combines scientific discussions with more practically focused case and tumor board-style elements in order to illustrate how innovative therapies, such as BTK, PI3K, and BCL-2 inhibitors, as well as IMiD-based regimens, are increasingly surpassing conventional options in the management of lymphoid cancers. Upon completion of this activity, participants should be better able to: Summarize recent efficacy and safety data associated with novel therapies, including BCR inhibitors, next-generation antibodies, BCL-2 inhibitors, and IMiDs, used to treat B-cell malignancies, Recommend novel agent classes for the treatment of newly diagnosed or relapsed/refractory B-cell malignancies, including for patients with CLL, FL, or MCL, Manage the unique spectrum of adverse events associated with the use of novel therapies in the management of B-cell malignancies

Go online to PeerView.com/RZK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PeerView's latest MasterClass and “Tumor Board” on demand activity is based on a live symposium at the 2019 hematologic malignancies meeting in Chicago and covers the ongoing integration of novel and next-generation therapeutics in the management of several B-cell malignancies, including follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL). This educational video activity combines scientific discussions with more practically focused case and tumor board-style elements in order to illustrate how innovative therapies, such as BTK, PI3K, and BCL-2 inhibitors, as well as IMiD-based regimens, are increasingly surpassing conventional options in the management of lymphoid cancers. Upon completion of this activity, participants should be better able to: Summarize recent efficacy and safety data associated with novel therapies, including BCR inhibitors, next-generation antibodies, BCL-2 inhibitors, and IMiDs, used to treat B-cell malignancies, Recommend novel agent classes for the treatment of newly diagnosed or relapsed/refractory B-cell malignancies, including for patients with CLL, FL, or MCL, Manage the unique spectrum of adverse events associated with the use of novel therapies in the management of B-cell malignancies

Go online to PeerView.com/RZK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PeerView's latest MasterClass and “Tumor Board” on demand activity is based on a live symposium at the 2019 hematologic malignancies meeting in Chicago and covers the ongoing integration of novel and next-generation therapeutics in the management of several B-cell malignancies, including follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL). This educational video activity combines scientific discussions with more practically focused case and tumor board-style elements in order to illustrate how innovative therapies, such as BTK, PI3K, and BCL-2 inhibitors, as well as IMiD-based regimens, are increasingly surpassing conventional options in the management of lymphoid cancers. Upon completion of this activity, participants should be better able to: Summarize recent efficacy and safety data associated with novel therapies, including BCR inhibitors, next-generation antibodies, BCL-2 inhibitors, and IMiDs, used to treat B-cell malignancies, Recommend novel agent classes for the treatment of newly diagnosed or relapsed/refractory B-cell malignancies, including for patients with CLL, FL, or MCL, Manage the unique spectrum of adverse events associated with the use of novel therapies in the management of B-cell malignancies

Go online to PeerView.com/RZK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PeerView's latest MasterClass and “Tumor Board” on demand activity is based on a live symposium at the 2019 hematologic malignancies meeting in Chicago and covers the ongoing integration of novel and next-generation therapeutics in the management of several B-cell malignancies, including follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL). This educational video activity combines scientific discussions with more practically focused case and tumor board-style elements in order to illustrate how innovative therapies, such as BTK, PI3K, and BCL-2 inhibitors, as well as IMiD-based regimens, are increasingly surpassing conventional options in the management of lymphoid cancers. Upon completion of this activity, participants should be better able to: Summarize recent efficacy and safety data associated with novel therapies, including BCR inhibitors, next-generation antibodies, BCL-2 inhibitors, and IMiDs, used to treat B-cell malignancies, Recommend novel agent classes for the treatment of newly diagnosed or relapsed/refractory B-cell malignancies, including for patients with CLL, FL, or MCL, Manage the unique spectrum of adverse events associated with the use of novel therapies in the management of B-cell malignancies

Go online to PeerView.com/RZK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PeerView's latest MasterClass and “Tumor Board” on demand activity is based on a live symposium at the 2019 hematologic malignancies meeting in Chicago and covers the ongoing integration of novel and next-generation therapeutics in the management of several B-cell malignancies, including follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL). This educational video activity combines scientific discussions with more practically focused case and tumor board-style elements in order to illustrate how innovative therapies, such as BTK, PI3K, and BCL-2 inhibitors, as well as IMiD-based regimens, are increasingly surpassing conventional options in the management of lymphoid cancers. Upon completion of this activity, participants should be better able to: Summarize recent efficacy and safety data associated with novel therapies, including BCR inhibitors, next-generation antibodies, BCL-2 inhibitors, and IMiDs, used to treat B-cell malignancies, Recommend novel agent classes for the treatment of newly diagnosed or relapsed/refractory B-cell malignancies, including for patients with CLL, FL, or MCL, Manage the unique spectrum of adverse events associated with the use of novel therapies in the management of B-cell malignancies

Go online to PeerView.com/RZK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PeerView's latest MasterClass and “Tumor Board” on demand activity is based on a live symposium at the 2019 hematologic malignancies meeting in Chicago and covers the ongoing integration of novel and next-generation therapeutics in the management of several B-cell malignancies, including follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL). This educational video activity combines scientific discussions with more practically focused case and tumor board-style elements in order to illustrate how innovative therapies, such as BTK, PI3K, and BCL-2 inhibitors, as well as IMiD-based regimens, are increasingly surpassing conventional options in the management of lymphoid cancers. Upon completion of this activity, participants should be better able to: Summarize recent efficacy and safety data associated with novel therapies, including BCR inhibitors, next-generation antibodies, BCL-2 inhibitors, and IMiDs, used to treat B-cell malignancies, Recommend novel agent classes for the treatment of newly diagnosed or relapsed/refractory B-cell malignancies, including for patients with CLL, FL, or MCL, Manage the unique spectrum of adverse events associated with the use of novel therapies in the management of B-cell malignancies